Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Scamthony Cataldo -- Ignore unavailable to you. Want to Upgrade?

To: TeamTi who wrote (15)	12/10/2003 10:19:11 PM
From: scion	Read Replies (1) \| Respond to of 137

In an early PR CYPT said this - Marr Technologies Limited is a member of the Marr Group of companies (the "Group"). The Group is a private group controlled by the Safin family and administered from London. Marat Safin, a London School of Economics graduate, is the President of the Group. The Group has a large and diverse number of investments and projects globally, principally in Europe, the Far East, the Middle East and the CIS, with substantial investments in telecoms and technology projects including its newly cquired "Green Plus Additive" which when added to fuel eliminates all traces of sulfur and increases power while cleaning up the environment. The Group has made significant progress in placing products and services of its group companies in the Chinese market and believes that its experience in China will greatly benefit the joint venture with Calypte. Since the SEC started asking questions about Marr their story has changed to Marr being a Mauritius "holding company" - but they still can't get the details well enough fudged to escape further investigation - by the SEC, and the UK Inland Revenue. Calypte Receives $10 Million Investment Company Raises $10,000,000 Via the Issuance of 20,000,000 Restricted Shares Of Common Stock From Treasury at a Price of $.50 Per Share With a One Year Lockup ALAMEDA, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test, announced a $10 million equity financing agreement with Marr Group via the issuance of 20,000,000 restricted shares of common stock from treasury at a price of $.50 per share. Commenting on the agreement, Tony Cataldo, Calypte's Executive Chairman stated, "We are delighted by the continued commitment to Calypte by Marr Group. This $10 million agreement brings a total of $12.5 million invested by Marr Group in Calypte over the past 30 days. With Marr's latest investment of $10 million we are confident that the company is sufficiently funded to execute our business plan." Marat Safin, Principal of Marr Technologies stated, "We feel that the current market is extremely strong for the products that Calypte has approved and ready to deliver. We are confident in the distribution network that is being put in place and impressed with the management team that will carryout the business plan. And finally our latest investment of $10 million will provide the cash needed to drive all these elements and move this company forward." About Marr Technologies Limited Marr Technologies Limited is a member of the Marr Group of companies (the "Group"). The Group is a private group controlled by the Safin family and administered from London. Marat Safin, a London School of Economics graduate, is the President of the Group. The Group has a large and diverse number of investments and projects globally, principally in Europe, the Far East, the Middle East and the CIS, with substantial investments in telecoms and technology projects including its newly acquired "Green Plus Additive" which when added to fuel eliminates all traces of sulfur and increases power while cleaning up the environment. The Group has made significant progress in placing products and services of its group companies in the Chinese market and believes that its experience in China will greatly benefit the joint venture with Calypte. About Calypte Biomedical: Calypte Biomedical Corporation headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners. Current product labeling including specific product performance claims can be found at www.calypte.com.

To: TeamTi who wrote (15)	12/11/2003 5:01:52 AM
From: RockyBalboa	Respond to of 137

As you mention EBI, just for the records a few documents on the local EAST founder: goldaura.com.au magnapacific.com.au He was the founder and a long time chairman of East Brokers Austria, an International diversified investment banking organisation and brokerage network with offices throughout US and Europe. He is currently a Director of Nautilus Management Consulting GMBH and Polinvest Beteiligungs AG. his company invested into local company, Coral: coralgold.com and ... ipo.onvista.de Where he was in with a chap named Briem whose former bank slipped into administration. Not surprisingly Ahag also went into receivership. One of the major shareholders is Millennium Capital Quest Corp. (USA). Ahag's main business was in the telephone trading of unlisted securities.